CymitQuimica logo

ML298

CAS:

Ref. 3D-BHC91602

5mg
355.00€
10mg
505.00€
25mg
897.00€
50mg
1,353.00€
100mg
2,108.00€
ML298
Biosynth

Product Information

Name:ML298
Brand:Biosynth
Description:ML298 is a cell culture-based drug that has been shown to inhibit tumor growth in cancer cells by inducing autophagy. It also enhances the transcriptional regulation of genes involved in cell proliferation, such as epidermal growth factor and E2F1, which are important for cellular proliferation. ML298 also inhibits inflammatory diseases by inhibiting the production of cytokines and chemokines. ML298 is currently being tested in clinical trials for its potential use in treating breast cancer, cervical cancer, colorectal carcinoma, and other cancers.ML298 is a monoclonal antibody with potent anti-tumor effects against various types of cancers. It binds to the epidermal growth factor receptor (EGFR) on cancer cells and blocks ligand binding to this receptor, which prevents activation of downstream signaling pathways. This leads to induction of autophagy (a process where cells degrade their own components) and inhibition of tumor growth by preventing proliferation and inducing apoptosis (
Notice:Our products are intended for lab use only. For any other use, please contact us.

Chemical properties

Molecular weight:432.44 g/mol
Formula:C22H23F3N4O2
Purity:Min. 95%

Technical inquiry about: ML298

Please use instead the cart to request a quotation or an order

If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
◻️
CYMIT QUÍMICA, S.L. as responsible for the treatment will treat your data in order to respond to your queries or requests. You can access, rectify and delete your data, as well as exercise other rights by consulting the additional and detailed information on data protection in our Web Privacy Policy.
* Mandatory fields.